tiprankstipranks
Blurbs

Analysts Conflicted on These Healthcare Names: Vericel (VCEL), Addus Homecare (ADUS) and Baxter International (BAX)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vericel (VCELResearch Report), Addus Homecare (ADUSResearch Report) and Baxter International (BAXResearch Report).

Vericel (VCEL)

BTIG analyst Ryan Zimmerman maintained a Buy rating on Vericel today and set a price target of $34.00. The company’s shares closed last Wednesday at $32.57.

According to TipRanks.com, Zimmerman is a 4-star analyst with an average return of 7.0% and a 44.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Treace Medical Concepts, and Organogenesis Holdings.

Vericel has an analyst consensus of Strong Buy, with a price target consensus of $41.25, representing a 29.4% upside. In a report issued on July 20, Truist Financial also maintained a Buy rating on the stock with a $33.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Addus Homecare (ADUS)

In a report released today, Ben Hendrix from RBC Capital maintained a Buy rating on Addus Homecare, with a price target of $110.00. The company’s shares closed last Wednesday at $93.70.

According to TipRanks.com, Hendrix is a 1-star analyst with an average return of -1.7% and a 50.9% success rate. Hendrix covers the Healthcare sector, focusing on stocks such as Aveanna Healthcare Holdings, Brookdale Senior Living, and Bright Health Group.

Currently, the analyst consensus on Addus Homecare is a Strong Buy with an average price target of $110.50, representing a 15.3% upside. In a report released today, Oppenheimer also maintained a Buy rating on the stock with a $130.00 price target.

Baxter International (BAX)

In a report released today, Amit Hazan from Goldman Sachs maintained a Sell rating on Baxter International, with a price target of $60.00. The company’s shares closed last Wednesday at $58.46, close to its 52-week low of $57.92.

According to TipRanks.com, Hazan is a 4-star analyst with an average return of 6.6% and a 56.7% success rate. Hazan covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Intuitive Surgical, and Outset Medical.

Currently, the analyst consensus on Baxter International is a Moderate Buy with an average price target of $70.73.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on VCEL:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles